Reginald B. Ewesuedo
Hematology | Oncology
7800 W Interstate 10 Ste 612
San Antonio, TX 78230
San Antonio, TX 78230
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: April 06, 2026
Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
Journal: Cancer chemotherapy and pharmacology
Published: March 06, 2026
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.
Journal: Clinical lung cancer
Published: April 10, 2025
LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Journal: Cancer research communications
Published: January 10, 2024
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
Journal: Cancer chemotherapy and pharmacology
Published: March 25, 2021
PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.
Journal: Advances in therapy
Published: April 08, 2020
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: July 12, 2019
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: March 29, 2019
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Journal: British journal of cancer
Published: February 22, 2018
Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 13, 2017
Evaluating imbalances of adverse events during biosimilar development.
Journal: mAbs
Published: April 07, 2016
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Journal: Cancer chemotherapy and pharmacology
Published: February 05, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026